Postoperative Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy in Cervical Cancer
Postoperative Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy in Cervical Cancer
To investigate the acute toxicities, late toxicities, and treatment results when the early
 cervical cancer patients are treated by concurrent chemotherapy with hypofractionated
 intensity-modulated radiotherapy (2.5 Gy X 16 fractions, once a day) after radical
 hysterectomy.
Inclusion Criteria:

 -  histologically confirmed cervical cancer

 -  radical hysterectomy and pelvic lymph node dissection was done

 -  histologically indicated adjuvant chemoradiotherapy (more than one as below)

 -  positive pelvic lymph node metastasis

 -  positive parametrial invasion

 -  positive tumor involvement on surgical margin

 -  ECOG performance status 0 or 1

 -  Bone marrow function: granulocyte ≥1.0 x 1000/µl, platelet ≥30 x 1000/µl, hemoglobin
 ≥10 g/dl

 -  Kidney function: Creatinine <2.0 mg/dL, Bilirubin 1.5 mg/dl

 Exclusion Criteria:

 -  positive distant metastasis (including retroperitoneal lymph node metastasis)

 -  previous history of pelvic radiotherapy

 -  more than 3 months after radical surgery for cervical cancer

 -  neoadjuvant chemotherapy was done

 -  previous history of other carcinoma except for thyroid cancer, skin cancer, in situ
 carcinoma on cervix